Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652196 · ClinicalTrials.gov registry record · Phase 2
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
A Phase 2 study, sponsored by John Hays.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT01652196 is a Phase 2 study that has completed, run by John Hays. The registered enrollment target is 56 participants.
The verdict
NCT01652196, a Phase 2 study, has completed, sponsored by John Hays.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be removed by surgery. Aflibercept may stop the growth of colon or rectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving aflibercept together with combination chemotherapy may kill more tumor cells
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin
- OTHER Correlative Studies
- BIOLOGICAL aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-11-14 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652196
The ClinicalTrials.gov registry entry for NCT01652196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Hays, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT01652196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01652196 about?
NCT01652196 is a clinical study titled "Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer". This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be removed by surgery. Aflibercept may stop the growth of colon or rectal cance...
What is the current status of trial NCT01652196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2012-11-14. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT01652196?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin (DRUG), Correlative Studies (OTHER), aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01652196?
This trial is sponsored by John Hays, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.